BG2103

BG2103 is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Guangzhou Bio-gene Technology. It consists of a patient's own T cells that have been genetically engineered to express a CAR targeting Claudin18.2 (CLDN18.2), a tight junction protein that is highly and selectively expressed on the surface of various tumor cells, particularly in gastric and pancreatic cancers. The mechanism of action involves the engineered CAR-T cells recognizing and binding to Claudin18.2 on tumor cell surfaces, which triggers T-cell activation and subsequent cytotoxic responses to eliminate the cancer cells. BG2103 is primarily being developed for the treatment of malignant gastric cancer and other Claudin18.2-positive solid tumors.